Acetazolamide in Patients With Acute Heart Failure (ACETA)
Introduction: Recent studies have suggested that the use of acetazolamide may assist in the vol- ume management of patients with decompensated heart failure (HF). However, prospective and randomized comparison in patients with HF and optimized diuretic therapy has not been described.
Objective: The aim of this study was to evaluate the effectiveness and safety of the use of acetazolamide versus placebo in volume control in patients with decompensated HF.
Methodology: For this, a unicentric, randomized, double blind and prospective study will be performed in a comparative manner. Hospital data (test results, medical outcomes, drug dose, complications) of patients will be analyzed for safety and effectiveness.
Expected results: The use of acetazolamide as an adjuvant treatment is superior to the standard strategy for volume control in patients with decompensated HF.
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation : Randomized
Intervention Model : Parallel Assignment
Masking : Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose : Treatment
Official Title : Prospective Analysis Between Acetazolamide vs Placebo in Patients With Acute Heart Failure
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : October 1, 2019
Estimated Study Completion Date : October 1, 2020
- Experimental: Acetazolamide
- Experimental: Placebo
|Date last updated at source||2018-10-30|
|Study start date||2018-10-01|
|Estimated primary completion date||2019-10-01|